Fast track trials for drug and vaccine development

Laura Fregonese (London, United Kingdom)

Source: International Congress 2016 – PG16 Infection control in epidemics: strengthening the evidence base for healthcare workers and the public

PDF journal article, handout or slidesPDF journal article, handout or slidesWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Laura Fregonese (London, United Kingdom). Fast track trials for drug and vaccine development. International Congress 2016 – PG16 Infection control in epidemics: strengthening the evidence base for healthcare workers and the public

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic
Source: Eur Respir Monogr 2021; 94: 39-68
Year: 2021


New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response
Source: Eur Respir Rev 2014; 23: 367-378
Year: 2014



How to accelerate bringing new drugs to patients: role of clinical trials networks
Source: International Congress 2019 – Rare lung diseases
Year: 2019


Vaccines - early clinical trials
Source: Virtual Congress 2020 – Management prevention
Year: 2020

Characterisation of clinical phenotypes is mandatory for the development of new drugs
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014

The future of translational lung cancer research: from classical randomised controlled trials to innovative platform trials
Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer
Year: 2018


Novel intradermal influenza vaccine: phase 3 data in targeted adult populations
Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care
Year: 2008


A randomised controlled trial comparing the immunogenicity, safety and tolerability of a 2012 trivalent seasonal inactivated influenza vaccine administered via a needless injector device versus a traditional pre-filled syringe and needle
Source: Annual Congress 2013 –Interesting cases of respiratory infections
Year: 2013


Comparative efficacy of the therapy strategies for the asthma control maintenance in real clinical practice
Source: Annual Congress 2011 - Asthma: control and treatment
Year: 2011


Safety and immunogenicity of a dose-sparing, trivalent inactivated seasonal influenza vaccine containing an advax adjuvant – a phase 1/2 randomised controlled trial
Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention
Year: 2008


Did inappropriate delivery systems hamper therapeutic efficacy of di-sodium-cromo-glycate (DSCG)? Time for a reappraisal
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011

Quality and methodology of clinical practice guidelines on antiviral pharmacotherapy for COVID-19 during the early phase of the pandemic
Source: Virtual Congress 2021 – COVID - 19: lessons learned
Year: 2021


Therapeutic drug monitoring practice in patients with active tuberculosis: assessment of opportunities
Source: Eur Respir J, 57 (1) 2002349; 10.1183/13993003.02349-2020
Year: 2021



Novel paradigm for inhaled therapies: simulation of drug pharmacokinetic behaviour and effect of disease
Source: Eur Respir J 2003; 22: Suppl. 45, 474s
Year: 2003

What could we learn from ongoing therapeutic trials?
Source: ERS Research Seminar
Year: 2015